Phosphodiesterase III & IV (PDE3 & PDE4)

Phosphodiesterases 3 and 4 are members of a superfamily of enzymes that terminate intracellular signaling mediated by cyclic nucleotides. PDE3 is particularly important in cardiovascular tissues, regulating myocardial contractility, vascular smooth muscle tone, and platelet function through its hydrolysis of cAMP and, to a lesser extent, cGMP. PDE4 is mainly expressed in immune and inflammatory cells where it exclusively hydrolyzes cAMP, thus influencing inflammatory responses. Both enzymes are proven therapeutic targets: PDE3 inhibitors are used in acute heart failure and vascular disorders, while PDE4 inhibitors are used in chronic obstructive pulmonary disease, psoriasis, and related inflammatory diseases. Dual inhibitors (such as ensifentrine) are in clinical development for pulmonary diseases. Safety concerns—especially increased arrhythmic risk for PDE3 and gastrointestinal or neuropsychiatric effects for PDE4—limit their clinical application and prompt careful patient selection and monitoring.

Other names

cGMP-inhibited phosphodiesterasecGMP-inhibited 3’,5’-cyclic phosphodiesterasecAMP-specific phosphodiesterasePDE3APDE3BPDE4APDE4B

PDE3 inhibitors: Increase intracellular cAMP (by preventing degradation), leading to positive inotropy (stronger heart contraction), vasodilation, inhibition of platelet aggregation, and bronchodilation. PDE4 inhibitors: Increase cAMP in inflammatory and immune cells, leading to decreased production of pro-inflammatory mediators and reduced inflammatory responses, primarily in lungs and skin. Both: bronchodilation in airway smooth muscle (relevant for COPD/asthma treatment). Dual PDE3/4 inhibition (e.g., ensifentrine): aims to combine bronchodilator and anti-inflammatory effects.